Loading...

Glaspy John

TitleDirector
InstitutionUniversity of California Los Angeles
DepartmentSurgical Oncology
Address100 Medical Plaza Suite 550
CAMPUS - 699624
Phone(310) 794-4955
vCardDownload vCard
    Other Positions
    TitleAssociate Chief

    TitleAssociate Professor


    Collapse Research 
    Collapse Research Activities and Funding
    CLINICAL EVALUATION OF BIOLOGICAL RESPONSE MODIFIERS
    NIH/NCI N01CM007439Sep 30, 1980
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, Ratikan JA, Felix C, Hwang L, Faull KF, Sayre JW, Hurvitz S, Glaspy J, Comin-Anduix B, Demaria S, Schaue D, McBride WH. Focal Irradiation and Systemic TGFß Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Feb 23. PMID: 29476019.
      View in: PubMed
    2. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018 Jun 10; 36(17):1658-1667. PMID: 28981385.
      View in: PubMed
    3. Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017 11; 25(11):3295-3304. PMID: 28842778.
      View in: PubMed
    4. Rugo HS, Seneviratne L, Beck JT, Glaspy J, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017 May; 18(5):654-662. PMID: 28314691.
      View in: PubMed
    5. de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017 06; 7(6):620-629. PMID: 28242752.
      View in: PubMed
    6. Blumenschein G, Chandler J, Garon EB, Waterhouse D, Goldman JW, Gunuganti VK, Boccia R, Spigel D, Glaspy J, Berry DA, Korytowsky B, Zhu J, Lin WH, Bennett K, Reynolds C. PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S307. PMID: 27969526.
      View in: PubMed
    7. Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, Campbell-Baird C, Hronek J, Seery V, Divers J, Glaspy J, Schmidt BL, Meiller TF. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016 Aug; 5(8):1897-907. PMID: 27334013; PMCID: PMC4971919.
    8. Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial. Pharmacotherapy. 2016 Apr; 36(4):402-14. PMID: 26927900.
      View in: PubMed
    9. Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M, Senzer NN. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer. 2016; 4:12. PMID: 26981242; PMCID: PMC4791835.
    10. Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy J, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix B. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016 Mar; 4(3):194-203. PMID: 26787823; PMCID: PMC4775381 [Available on 03/01/17].
    11. Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy J, Puccio-Pick M, Zou J, Crawford J. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016 Apr; 24(4):1517-25. PMID: 26370220; PMCID: PMC4766217.
    12. Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy J, Kim KB, Hwu WJ, Ribas A. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015 Nov; 51(17):2689-97. PMID: 26364516; PMCID: PMC4821004 [Available on 11/01/16].
    13. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy J, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27; 515(7528):568-71. PMID: 25428505; PMCID: PMC4246418.
    14. Shander A, Goodnough LT, Javidroozi M, Auerbach M, Carson J, Ershler WB, Ghiglione M, Glaspy J, Lew I. Iron deficiency anemia--bridging the knowledge and practice gap. Transfus Med Rev. 2014 Jul; 28(3):156-66. PMID: 24931617.
      View in: PubMed
    15. Glaspy J. Current status of use of erythropoietic agents in cancer patients. Semin Thromb Hemost. 2014 Apr; 40(3):306-12. PMID: 24676903.
      View in: PubMed
    16. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy J, Witte ON, Baltimore D, Economou JS, Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. PMID: 24634374; PMCID: PMC4070853.
    17. Ribas A, Zhang W, Chang I, Shirai K, Ernstoff MS, Daud A, Cowey CL, Daniels G, Seja E, O'Laco E, Glaspy J, Chmielowski B, Hill T, Joe AK, Grippo JF. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014 Apr; 54(4):368-74. PMID: 24374975.
      View in: PubMed
    18. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy J, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93. PMID: 24265155; PMCID: PMC3936420.
    19. Deitcher OR, Glaspy J, Gonzalez R, Sato T, Bedikian AY, Segarini K, Silverman J, Deitcher SR. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):197-202. PMID: 24417913.
      View in: PubMed
    20. Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist. 2013; 18(7):812-8. PMID: 23814044; PMCID: PMC3720634.
    21. Rosove MH, Peddi PF, Glaspy J. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013 Feb 14; 368(7):684-5. PMID: 23406047.
      View in: PubMed
    22. Vansteenkiste J, Wauters I, Elliott S, Glaspy J, Hedenus M. Chemotherapy-induced anemia: the story of darbepoetin alfa. Curr Med Res Opin. 2013 Apr; 29(4):325-37. PMID: 23323876.
      View in: PubMed
    23. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan; 14(1):72-80. PMID: 23246022.
      View in: PubMed
    24. Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy J, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236. PMID: 23171508; PMCID: PMC3543342.
    25. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy J, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012 Sep; 2(9):791-7. PMID: 22798288; PMCID: PMC3449158.
    26. Glaspy J. Update on safety of ESAs in cancer-induced anemia. J Natl Compr Canc Netw. 2012 May; 10(5):659-66. PMID: 22570294.
      View in: PubMed
    27. Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer. 2012 Jun; 76(3):478-85. PMID: 22277104.
      View in: PubMed
    28. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy J, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011; 6(12):e28973. PMID: 22194965; PMCID: PMC3237573.
    29. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 06; 365(14):1273-83. PMID: 21991949; PMCID: PMC3268553.
    30. Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy J, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011 May 24; 9:76. PMID: 21609436; PMCID: PMC3152784.
    31. Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011; 16(8):1092-100. PMID: 21572124; PMCID: PMC3228158.
    32. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy J, Cochran AJ, Ribas A. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011 Jun 15; 17(12):4101-9. PMID: 21558401; PMCID: PMC3117971.
    33. Glaspy J. Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson. Oncology (Williston Park). 2011 Apr 30; 25(5):423-4. PMID: 21710839.
      View in: PubMed
    34. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 01; 29(10):1252-60. PMID: 21383283.
      View in: PubMed
    35. Glaspy J. Randomized controlled trials of the erythroid-stimulating agents in cancer patients. Cancer Treat Res. 2011; 157:195-215. PMID: 21052958.
      View in: PubMed
    36. Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy J, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med. 2010 Sep 27; 8:89. PMID: 20875102; PMCID: PMC2954849.
    37. Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010 Sep 15; 116(18):4227-37. PMID: 20549829.
      View in: PubMed
    38. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy J, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia. 2010 Aug; 12(8):637-49. PMID: 20689758; PMCID: PMC2915408.
    39. Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Clin Breast Cancer. 2010 Aug 01; 10(4):307-12. PMID: 20705564.
      View in: PubMed
    40. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010 Jul; 122(1):181-8. PMID: 20361252.
      View in: PubMed
    41. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010 Jan 19; 102(2):301-15. PMID: 20051958; PMCID: PMC2816662.
    42. Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer. 2010 Jan 01; 116(1):146-54. PMID: 19862820.
      View in: PubMed
    43. Ribas A, Chmielowski B, Glaspy J. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009 Dec 01; 15(23):7116-8. PMID: 19934296.
      View in: PubMed
    44. Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer. 2009 Nov 15; 115(22):5228-36. PMID: 19728370.
      View in: PubMed
    45. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 01; 27(34):5763-71. PMID: 19884534.
      View in: PubMed
    46. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy J, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009 Oct 01; 15(19):6267-76. PMID: 19789309; PMCID: PMC2765061.
    47. Naeim A, Friedman L, Whitlock KB, Pasta DJ, Elkin EP, Lubeck DP, Viswanathan HN, Glaspy J. Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy. J Oncol Pract. 2009 Sep; 5(5):236-43. PMID: 20856735; PMCID: PMC2790673.
    48. Glaspy J. Hematology: ESAs to treat anemia--balancing the risks and benefits. Nat Rev Clin Oncol. 2009 Sep; 6(9):500-2. PMID: 19707239.
      View in: PubMed
    49. Glaspy J, Ribas A, Chmielowski B. Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? J Clin Oncol. 2009 Jun 20; 27(18):2896-7. PMID: 19433677.
      View in: PubMed
    50. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy J. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009 Jun 10; 27(17):2838-47. PMID: 19380447.
      View in: PubMed
    51. Glaspy J, Charu V, Luo D, Moyo V, Kamin M, Wilhelm FE. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer. 2009 Mar 01; 115(5):1121-31. PMID: 19170225.
      View in: PubMed
    52. Glaspy J. Erythropoietin in cancer patients. Annu Rev Med. 2009; 60:181-92. PMID: 18980468.
      View in: PubMed
    53. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy J, Gomez-Navarro J, Cochran AJ. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res. 2009 Jan 01; 15(1):390-9. PMID: 19118070.
      View in: PubMed
    54. Glaspy J. Erythropoiesis-stimulating agents in oncology. J Natl Compr Canc Netw. 2008 Jul; 6(6):565-75. PMID: 18597710.
      View in: PubMed
    55. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy J, Gomez-Navarro J, Ribas A. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008 May 01; 6:22. PMID: 18452610; PMCID: PMC2412852.
    56. Aapro MS, Birgegård G, Bokemeyer C, Cornes P, Foubert J, Gascon P, Glaspy J, Hellström-Lindberg E, Link H, Ludwig H, Osterborg A, Repetto L, Soubeyran P. Erythropoietins should be used according to guidelines. Lancet Oncol. 2008 May; 9(5):412-3. PMID: 18452853.
      View in: PubMed
    57. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy J, Economou JS, Ribas A. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008 Apr; 31(3):294-309. PMID: 18317358; PMCID: PMC3651040.
    58. Rodgers GM, Auerbach M, Cella D, Chertow GM, Coyne DW, Glaspy J, Henry DH. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol. 2008 May; 19(5):833-4. PMID: 18369084.
      View in: PubMed
    59. Smith RE, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy J. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008 Mar 01; 26(7):1040-50. PMID: 18227526.
      View in: PubMed
    60. Rubin RJ, Glaspy J, Adams JL, Mafilios MS, Wang SM, Viswanathan HN, Kallich JD. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective. J Med Econ. 2008; 11(2):199-213. PMID: 19450080.
      View in: PubMed
    61. Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist. 2007 Oct; 12(10):1253-63. PMID: 17962619.
      View in: PubMed
    62. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007 May 05; 369(9572):1502-4. PMID: 17482969.
      View in: PubMed
    63. Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy J, Bozon V, Gomez-Navarro J, Ribas A. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol. 2007 Jun; 143(6):958-969. PMID: 17434437.
      View in: PubMed
    64. Hirsh V, Glaspy J, Mainwaring P, Manegold C, Ramlau R, Eid JE. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Trials. 2007 Mar 06; 8:8. PMID: 17341293; PMCID: PMC1831793.
    65. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy J, Aronson WJ. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006 Aug 01; 12(15):4662-70. PMID: 16899616; PMCID: PMC3410648.
    66. Glaspy J. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia. Oncology (Williston Park). 2006 Jul; 20(8 Suppl 6):29-32. PMID: 16925109.
      View in: PubMed
    67. Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol. 2006 May 20; 24(15):2290-7. PMID: 16710026.
      View in: PubMed
    68. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy J, Economou JS. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006 May 01; 12(9):2817-25. PMID: 16675576.
      View in: PubMed
    69. Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy J, McBride WH, Bonavida B, Economou JS, Ribas A. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol. 2006 Apr 15; 176(8):4757-65. PMID: 16585569.
      View in: PubMed
    70. Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer. 2006 Jan 01; 106(1):223-33. PMID: 16331597.
      View in: PubMed
    71. Comin-Anduix B, Gualberto A, Glaspy J, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res. 2006 Jan 01; 12(1):107-16. PMID: 16397031.
      View in: PubMed
    72. Glaspy J. Cancer patient survival and erythropoietin. J Natl Compr Canc Netw. 2005 Nov; 3(6):796-804. PMID: 16316615.
      View in: PubMed
    73. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy J, Gomez-Navarro J. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005 Dec 10; 23(35):8968-77. PMID: 16204013.
      View in: PubMed
    74. Crawford J, Glaspy J, Stoller RG, Tomita DK, Vincent ME, McGuire BW, Ozer H. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005 Oct 01; 3(1):36-46. PMID: 18632435.
      View in: PubMed
    75. Glaspy J. Every-three-week erythropoietic support during chemotherapy for cancer: current status and future issues. Support Cancer Ther. 2005 Oct 01; 3(1):16-20. PMID: 18632430.
      View in: PubMed
    76. Ribas A, Vo DD, Weeks DL, Comin-Anduix B, Schumacher LY, Garban HJ, McLean C, Yang J, Dissette VB, Peraza P, Owens SK, McBride WH, Glaspy J, Economou JS. Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother. 2006 Jun; 55(6):663-71. PMID: 16133107.
      View in: PubMed
    77. Glaspy J. The development of erythropoietic agents in oncology. Expert Opin Emerg Drugs. 2005 Aug; 10(3):553-67. PMID: 16083329.
      View in: PubMed
    78. Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy J, McBride WH, Butterfield LH, Economou JS, Ribas A. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther. 2005 Jun; 12(6):516-27. PMID: 15775996.
      View in: PubMed
    79. Glaspy J, Henry D, Patel R, Tchekmedyian S, Applebaum S, Berdeaux D, Lloyd R, Berg R, Austin M, Rossi G. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer. 2005 May; 41(8):1140-9. PMID: 15911237.
      View in: PubMed
    80. Glaspy J. Entering a new era in the management of tumor-associated involution. J Support Oncol. 2005 Jan-Feb; 3(1):51-2. PMID: 15724945.
      View in: PubMed
    81. Berndt E, Kallich J, McDermott A, Xu X, Lee H, Glaspy J. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics. 2005; 23(5):505-14. PMID: 15896101.
      View in: PubMed
    82. Chamras H, Barsky SH, Ardashian A, Navasartian D, Heber D, Glaspy J. Novel interactions of vitamin E and estrogen in breast cancer. Nutr Cancer. 2005; 52(1):43-8. PMID: 16091003.
      View in: PubMed
    83. Glaspy J, Beguin Y. Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon). Oncology. 2005; 69 Suppl 2:8-16. PMID: 16244505.
      View in: PubMed
    84. Glaspy J. Phase III clinical trials with darbepoetin: implications for clinicians. Best Pract Res Clin Haematol. 2005; 18(3):407-16. PMID: 15792914.
      View in: PubMed
    85. Ribas A, Glaspy J, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother. 2004 Sep-Oct; 27(5):354-67. PMID: 15314544.
      View in: PubMed
    86. Gordon LK, Ribas A, Nusinowitz S, Butterfield LH, Glaspy J, Economou JS, Straatsma BR. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Control Clin Trials. 2004 Aug; 25(4):400-7. PMID: 15296814.
      View in: PubMed
    87. Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy J, McBride WH, Butterfield LH, Economou JS. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol. 2004 Apr 15; 172(8):4762-9. PMID: 15067052.
      View in: PubMed
    88. Glaspy J, Dunst J. Can erythropoietin therapy improve survival? Oncology. 2004; 67 Suppl 1:5-11. PMID: 15486447.
      View in: PubMed
    89. Glaspy J. Hematopoietic management in oncology practice. Part 2. Erythropoietic factors. Oncology (Williston Park). 2003 Dec; 17(12):1724-30; discussion 1731-2, 1735, 1739. PMID: 14723012.
      View in: PubMed
    90. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy J, McBride WH, Economou JS. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5902-8. PMID: 14676113.
      View in: PubMed
    91. Glaspy J. Hematopoietic management in oncology practice. Part 1. Myeloid growth factors. Oncology (Williston Park). 2003 Nov; 17(11):1593-603. PMID: 14682110.
      View in: PubMed
    92. Smith JR, Glaspy J, Tchekmedyian NS, Austin MD, Kallich JD. Hemoglobin increase is associated with improved health-related quality of life in patients with cancer not receiving chemotherapy. Support Cancer Ther. 2003 Oct 01; 1(1):49-54. PMID: 18628131.
      View in: PubMed
    93. Ribas A, Butterfield LH, Glaspy J, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003 Jun 15; 21(12):2415-32. PMID: 12805342.
      View in: PubMed
    94. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther. 2003 Jun; 25(6):1786-805. PMID: 12860499.
      View in: PubMed
    95. O'Day SJ, Agarwala SS, Naredi P, Kass CL, Gehlsen KR, Glaspy J. Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. Melanoma Res. 2003 Jun; 13(3):307-11. PMID: 12777988.
      View in: PubMed
    96. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003 May-Jun; 10(3):715-24. PMID: 12684649.
      View in: PubMed
    97. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006. PMID: 12637463.
      View in: PubMed
    98. Glaspy J, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer. 2003 Mar 01; 97(5):1312-20. PMID: 12599240.
      View in: PubMed
    99. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy J, Economou JS. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003 Mar; 9(3):998-1008. PMID: 12631598.
      View in: PubMed
    100. Bagga D, Wang L, Farias-Eisner R, Glaspy J, Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1751-6. PMID: 12578976; PMCID: PMC149905.
    101. Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer. 2003 Feb; 3(6):391-8. PMID: 12636878.
      View in: PubMed
    102. Beusterien KM, Ackerman SJ, Plante K, Glaspy J, Naredi P, Wood D, Gehlsen K, Agarwala SS. The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. Support Care Cancer. 2003 May; 11(5):304-12. PMID: 12720074.
      View in: PubMed
    103. Chamras H, Ardashian A, Heber D, Glaspy J. Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J Nutr Biochem. 2002 Dec; 13(12):711-716. PMID: 12550055.
      View in: PubMed
    104. Catlin DH, Breidbach A, Elliott S, Glaspy J. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem. 2002 Nov; 48(11):2057-9. PMID: 12406997.
      View in: PubMed
    105. Ribas A, Amarnani SN, Buga GM, Butterfield LH, Dissette VB, McBride WH, Glaspy J, Ignarro LJ, Economou JS. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines. Cancer Gene Ther. 2002 Nov; 9(11):875-83. PMID: 12386826.
      View in: PubMed
    106. Glaspy J, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Williston Park). 2002 Oct; 16(10 Suppl 11):23-9. PMID: 12435170.
      View in: PubMed
    107. Vansteenkiste J, Poulsen E, Rossi G, Glaspy J. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations. Oncology (Williston Park). 2002 Oct; 16(10 Suppl 11):45-55. PMID: 12435173.
      View in: PubMed
    108. Glaspy J. The potential for anemia treatment to improve survival in cancer patients. Oncology (Williston Park). 2002 Sep; 16(9 Suppl 10):35-40. PMID: 12380953.
      View in: PubMed
    109. Glaspy J. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency. Oncology (Williston Park). 2002 Sep; 16(9 Suppl 10):71-7. PMID: 12380957.
      View in: PubMed
    110. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy J. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002 Aug 15; 95(4):888-95. PMID: 12209734.
      View in: PubMed
    111. Shen J, Andersen R, Albert PS, Wenger N, Glaspy J, Cole M, Shekelle P. Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med. 2002 Aug 13; 2:8. PMID: 12175424; PMCID: PMC122074.
    112. Langer CJ, Choy H, Glaspy J, Colowick A. Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer. 2002 Aug 01; 95(3):613-23. PMID: 12209755.
      View in: PubMed
    113. Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O'Byrne J, Rossi G, Colowick AB. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer. 2002 Jul 29; 87(3):268-76. PMID: 12177793; PMCID: PMC2364226.
    114. Middleton M, Sarno M, Agarwala SS, Glaspy J, Laurent A, McMasters K, Naredi P, O'Day S, Whitman E, Danson S, Cosford R, Gehlsen K. Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. J Clin Pharmacol. 2002 Jul; 42(7):774-81. PMID: 12092744.
      View in: PubMed
    115. Glaspy J. Therapeutic options in the management of renal cell carcinoma. Semin Oncol. 2002 Jun; 29(3 Suppl 7):41-6. PMID: 12068388.
      View in: PubMed
    116. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy J. Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. Exp Hematol. 2002 Apr; 30(4):374-80. PMID: 11937274.
      View in: PubMed
    117. Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Glaspy J. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer. 2002 Apr; 3(1):45-51. PMID: 12020395.
      View in: PubMed
    118. Ribas A, Butterfield LH, Glaspy J, Economou JS. Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther. 2002 Feb; 2(1):57-78. PMID: 12108974.
      View in: PubMed
    119. Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, Glaspy J. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer. 2002 Feb; 3(3):180-90. PMID: 14662041.
      View in: PubMed
    120. Bagga D, Anders KH, Wang HJ, Glaspy J. Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer. Nutr Cancer. 2002; 42(2):180-5. PMID: 12416257.
      View in: PubMed
    121. Glaspy J, Degos L, Dicato M, Demetri GD. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist. 2002; 7(2):126-35. PMID: 11961196.
      View in: PubMed
    122. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33. PMID: 11773161.
      View in: PubMed
    John's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _